Combining Procalcitonin and Calcitonin for the Diagnosis of Medullary Thyroid Cancer: A Two‐Step Approach
Clinical Endocrinology · 2025
DOI: 10.1111/cen.15287 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Endocrinology, 2025. Verfasst von Cristina Clausi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (DIMED), University of Padua, Padova, Italy. Hauptthemen laut MEDLINE: Procalcitonin, Calcitonin, Thyroid Neoplasms, Carcinoma, Neuroendocrine. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Objective
Calcitonin (CT) represents the most important biochemical marker of medullary thyroid cancer (MTC), but has certain limits. Procalcitonin (ProCT) has been recognized as an alternative or additional marker for MTC. The aim of the study is to evaluate prospectively the role of ProCT combined with CT in the identification of MTC.
Design
Patients and measurements: 478 patients undergoing thyroidectomy in Padua between January 2023 and June 2024 were enrolled to investigate ProCT levels in comparison with CT for MTC diagnosis. Serum levels of ProCT and CT were dosed preoperatively.
Results
At histological diagnosis, 23/478 (4.8%) patients tested positive for MTC. CT with a cut‐off > 10 pg/mL performed as follows: sensitivity 0.91, specificity 0.98, positive predictive value (PPV) 0.7, negative predictive value (NPV) 0.99. CT with a cut‐off > 10 pg/mL performed better than ProCT both using the cut‐off of 0.04 ng/mL (sensitivity 0.87; specificity 0.96; PPV 0.56; NPV 0.99) and the cut‐off of 0.07 ng/mL (sensitivity 0.78; specificity 0.98; PPV 0.72; NPV 0.99). Within the sample of patients with a CT value between 10 and 100 pg/mL, 17/21 (80.9%) patients would have been correctly identified as MTC or non‐MTC based on a positive or negative ProCT using the 0.04 ng/mL cut‐off.
Conclusions
CT is more sensitive than ProCT as a diagnostic marker for MTC. However, a two‐step approach using ProCT as a supplementary marker can help to refine the diagnosis avoiding overtreatment, particularly when CT serum levels lie between 10 and 100 pg/mL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (DIMED), University of Padua, Padova, Italy.
- Endocrinology Unit, University Hospital of Padova, Padova, Italy.
- Laboratory Medicine, Department of Medical and Surgical Sciences, University of Padua, Padua, Italy.
- Endocrine Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DiSCOG), University of Padua, Padua, Italy.
ORCID-Profile: Simona Censi
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Clausi, C., Censi, S., Zanin, E., Messina, G., Piva, I., Basso, D., Merante Boschin, I., Bertazza, L., Torresan, F., Iacobone, M., Battheu, F., Barollo, S., Arnone, J. M., & Mian, C. (2025). Combining Procalcitonin and Calcitonin for the Diagnosis of Medullary Thyroid Cancer: A Two‐Step Approach. Clinical Endocrinology. https://doi.org/10.1111/cen.15287
Vancouver
Clausi C, Censi S, Zanin E, Messina G, Piva I, Basso D, et al. Combining Procalcitonin and Calcitonin for the Diagnosis of Medullary Thyroid Cancer: A Two‐Step Approach. Clinical Endocrinology. 2025. doi:10.1111/cen.15287
BibTeX
@article{Clausi2025,
author = {Clausi, Cristina and Censi, Simona and Zanin, Emma and Messina, Giulia and Piva, Ilaria and Basso, Daniela and Merante Boschin, Isabella and Bertazza, Loris and Torresan, Francesca and Iacobone, Maurizio and Battheu, Fiammetta and Barollo, Susi and Arnone, Jacopo Maria and Mian, Caterina},
title = {Combining Procalcitonin and Calcitonin for the Diagnosis of Medullary Thyroid Cancer: A Two‐Step Approach},
journal = {Clinical Endocrinology},
year = {2025},
doi = {10.1111/cen.15287}
}
EUVIMED